185 related articles for article (PubMed ID: 20425349)
1. Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy.
Ohno R;
Curr Hematol Malig Rep; 2006 Sep; 1(3):180-7. PubMed ID: 20425349
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Thomas DA; Faderl S; Cortes J; O'Brien S; Giles FJ; Kornblau SM; Garcia-Manero G; Keating MJ; Andreeff M; Jeha S; Beran M; Verstovsek S; Pierce S; Letvak L; Salvado A; Champlin R; Talpaz M; Kantarjian H
Blood; 2004 Jun; 103(12):4396-407. PubMed ID: 14551133
[TBL] [Abstract][Full Text] [Related]
3. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Ravandi F; Jorgensen JL; Thomas DA; O'Brien S; Garris R; Faderl S; Huang X; Wen S; Burger JA; Ferrajoli A; Kebriaei P; Champlin RE; Estrov Z; Challagundla P; Wang SA; Luthra R; Cortes JE; Kantarjian HM
Blood; 2013 Aug; 122(7):1214-21. PubMed ID: 23836561
[TBL] [Abstract][Full Text] [Related]
4. Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias.
Gupta V; Kamel-Reid S; Minden MD; Lipton JH; Brandwein J; Messner HA
Hematology; 2003 Jun; 8(3):139-43. PubMed ID: 12745646
[TBL] [Abstract][Full Text] [Related]
5. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
Strati P; Kantarjian H; Thomas D; O'Brien S; Konoplev S; Jorgensen JL; Luthra R; Abruzzo L; Jabbour E; Quintas-Cardama A; Borthakur G; Faderl S; Ravandi F; Cortes J
Cancer; 2014 Feb; 120(3):373-80. PubMed ID: 24151050
[TBL] [Abstract][Full Text] [Related]
6. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
7. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
[TBL] [Abstract][Full Text] [Related]
8. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
de Labarthe A; Rousselot P; Huguet-Rigal F; Delabesse E; Witz F; Maury S; Réa D; Cayuela JM; Vekemans MC; Reman O; Buzyn A; Pigneux A; Escoffre M; Chalandon Y; MacIntyre E; Lhéritier V; Vernant JP; Thomas X; Ifrah N; Dombret H;
Blood; 2007 Feb; 109(4):1408-13. PubMed ID: 17062730
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Verma D; Kantarjian HM; Jones D; Luthra R; Borthakur G; Verstovsek S; Rios MB; Cortes J
Blood; 2009 Sep; 114(11):2232-5. PubMed ID: 19531657
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.
Chalandon Y; Thomas X; Hayette S; Cayuela JM; Abbal C; Huguet F; Raffoux E; Leguay T; Rousselot P; Lepretre S; Escoffre-Barbe M; Maury S; Berthon C; Tavernier E; Lambert JF; Lafage-Pochitaloff M; Lhéritier V; Chevret S; Ifrah N; Dombret H;
Blood; 2015 Jun; 125(24):3711-9. PubMed ID: 25878120
[TBL] [Abstract][Full Text] [Related]
12. New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.
Thomas DA; O'Brien S; Cortes J; Kantarjian H
Curr Hematol Malig Rep; 2007 Jul; 2(3):183-9. PubMed ID: 20425368
[TBL] [Abstract][Full Text] [Related]
13. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
14. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
[TBL] [Abstract][Full Text] [Related]
16. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Stock W
Leuk Lymphoma; 2010 Feb; 51(2):188-98. PubMed ID: 20001232
[TBL] [Abstract][Full Text] [Related]
17. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
Towatari M; Yanada M; Usui N; Takeuchi J; Sugiura I; Takeuchi M; Yagasaki F; Kawai Y; Miyawaki S; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Blood; 2004 Dec; 104(12):3507-12. PubMed ID: 15315963
[TBL] [Abstract][Full Text] [Related]
18. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Wassmann B; Pfeifer H; Goekbuget N; Beelen DW; Beck J; Stelljes M; Bornhäuser M; Reichle A; Perz J; Haas R; Ganser A; Schmid M; Kanz L; Lenz G; Kaufmann M; Binckebanck A; Brück P; Reutzel R; Gschaidmeier H; Schwartz S; Hoelzer D; Ottmann OG
Blood; 2006 Sep; 108(5):1469-77. PubMed ID: 16638934
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
Koca E; Sevimli F; Cetiner D; Haznedaroglu IC; Sayinalp N; Büyükasik Y; Goker H; Ozcebe O
Am J Hematol; 2007 Apr; 82(4):333. PubMed ID: 17094091
[No Abstract] [Full Text] [Related]
20. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
